5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Five retirees do a conga line dance on the beach celebrating the special dividend announced by Grange Resources today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One lesson out of last month's reporting season was that cost pressures are persisting for ASX-listed companies.

That's the analysis from Wilsons equity strategist Rob Crookston, who argued that the biggest pressure for businesses at the moment is labour costs.

"For instance, Cleanaway Waste Management Ltd (ASX: CWY) reported a heightened number of job vacancies caused employee costs to rise +16% due to the need to pay more overtime and use more expensive labour hire contractors," he said in a Wilsons memo to clients.

While in the longer term, inflation will settle down, according to Crookston, its effects can't be ignored when deciding which ASX shares to buy at the moment.

"The near-term threat to profitability is… meaningful and we see further downside to margins from here, particularly in more cyclical sectors with less pricing power — e.g. retail, discretionary goods."

So which are the best ASX shares to buy under such conditions?

Nothing beats setting your own prices

According to Crookston, "the best defence against cost inflation is pricing power".

"High quality companies with resilient customer demand through the cycle and dominant market positions operating in attractive industry structures are best placed to protect their margins by raising prices."

He named five such S&P/ASX 200 Index (ASX: XJO) stocks that the Wilsons team holds in its focus portfolio:

CSL can set its own prices as the "dominant and lowest-cost player" in the international blood plasma industry, said Crookston.

"The market for immunoglobulin (IG) products is supply constrained, while underlying demand is highly defensive given IG is used to treat patients with a range of serious immunologic and neurologic diseases."

Another medical player, ResMed, already has about 70% of the sleep apnea device market. According to Crookston, it's on its way to supplying the entire market because its nearest rival, Koninklijke Philips NV (AMS: PHIA), is still hamstrung from a 2021 product recall.

Telstra, whose dominance goes without saying for most Australians, is "committed to raising prices annually (and cutting costs) to offset inflation".

"Mobile net ads were strong in 1H23 in spite of higher prices, and the competitive setting is increasingly rational."

In the recession-resilient insurance industry, IAG can name its own prices.

"Number 1 general insurer in Australia, which has been [raising] premium rates strongly to offset rising perils costs (albeit there is a timing lag to margins)," said Crookston.

"Even with higher premiums, customer retention rates remain high."

He noted that The Lottery Corporation operates in a monopoly in every state except for Western Australia.

"Lottery sales have historically been [highly] resilient in economic downturns, and TLC has a proven ability to incrementally raise ticket prices over time."

Motley Fool contributor Tony Yoo has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Morgans says these are some of the very best ASX 200 shares to buy

The broker believes these shares could be destined to deliver big returns.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

Where to invest $8,000 on the ASX in April 2024

A leading broker thinks these shares would be quality options this month.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Happy couple doing grocery shopping together.
Broker Notes

Buy one, sell the other: Goldman's verdict on Coles vs. Woolworths share prices

One stock is set for a 26% share price gain over the next 12 months while the other is destined…

Read more »

Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

These ASX 200 shares could rise 20% to 50%

Big returns could be on the cards for owners of these shares according to analysts.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »